Pages that link to "Q43674732"

The following pages link to Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). (Q43674732):

Displaying 100 items.

• Reverse transcription of the HIV-1 pandemic (Q22242815) (← links)
• Adherence and drug resistance: predictions for therapy outcome (Q27477742) (← links)
• Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations (Q28235418) (← links)
• In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues (Q28343615) (← links)
• Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice (Q28343930) (← links)
• Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine (Q28344137) (← links)
• A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine (Q28379499) (← links)
• Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years (Q28379519) (← links)
• "Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice (Q28477270) (← links)
• Patterns of transmitted HIV drug resistance in Europe vary by risk group (Q28537726) (← links)
• Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro (Q28542490) (← links)
• Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. (Q29619254) (← links)
• Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee (Q33442370) (← links)
• Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients (Q33586790) (← links)
• Managing resistance to anti-HIV drugs: an important consideration for effective disease management. (Q33588535) (← links)
• Selection of drug-resistant HIV. (Q33594382) (← links)
• Evolutionary dynamics of HIV-induced subversion of the immune response (Q33683341) (← links)
• Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus-infected patients (Q33699597) (← links)
• British HIV Association guidelines for prescribing antiretroviral therapy in pregnancy (1998). (Q33711667) (← links)
• A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host. (Q33728690) (← links)
• Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase (Q33737755) (← links)
• Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication (Q33743954) (← links)
• A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine (Q33782477) (← links)
• Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy (Q33782492) (← links)
• Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro (Q33782815) (← links)
• Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy (Q33784635) (← links)
• Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy (Q33825371) (← links)
• Human immunodeficiency virus drug resistance testing: state of the art in genotypic and phenotypic testing of antiretrovirals (Q33839756) (← links)
• Population genetic analysis of the protease locus of human immunodeficiency virus type 1 quasispecies undergoing drug selection, using a denaturing gradient-heteroduplex tracking assay (Q33843999) (← links)
• Genotypic testing for human immunodeficiency virus type 1 drug resistance (Q33906239) (← links)
• Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase (Q33961507) (← links)
• Incidence and impact of resistance against approved antiretroviral drugs (Q33966248) (← links)
• A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC) (Q33976011) (← links)
• Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine (Q33977402) (← links)
• Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus (Q33981009) (← links)
• Inhibitors of HIV-1 reverse transcriptase (Q34050684) (← links)
• Antiretroviral therapy for human immunodeficiency virus infection in 1997 (Q34185841) (← links)
• Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase (Q34339657) (← links)
• Differential susceptibility of retroviruses to nucleoside analogues (Q34349394) (← links)
• Virus population dynamics, fitness variations and the control of viral disease: an update (Q34452529) (← links)
• Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. (Q34465037) (← links)
• Rapid emergence of protease inhibitor resistance in hepatitis C virus (Q34551913) (← links)
• The effects of internal primer-template mismatches on RT-PCR: HIV-1 model studies (Q34625250) (← links)
• The HBV drug entecavir - effects on HIV-1 replication and resistance (Q34639926) (← links)
• Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. (Q34644794) (← links)
• The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase (Q34668716) (← links)
• Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity. (Q34677368) (← links)
• HIV-1 genotypic and phenotypic resistance (Q34876000) (← links)
• Antivirals against HIV-1. (Q34876093) (← links)
• 4'-C-methyl-2'-deoxyadenosine and 4'-C-ethyl-2'-deoxyadenosine inhibit HIV-1 replication (Q34933164) (← links)
• HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya (Q34968326) (← links)
• HIV-1 drug resistance: can we overcome? (Q34974754) (← links)
• Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening (Q35014297) (← links)
• Managing failure to antiretroviral drugs in HIV-1-infected patients (Q35063764) (← links)
• Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors (Q35130447) (← links)
• Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice (Q35139305) (← links)
• Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine (Q35139503) (← links)
• High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis. (Q35156558) (← links)
• Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. (Q35363594) (← links)
• Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase (Q35548123) (← links)
• Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase (Q35566910) (← links)
• Update on HIV resistance and resistance testing (Q35574598) (← links)
• Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1 (Q35579833) (← links)
• Hepatitis B viral resistance: mechanisms and diagnosis (Q35621686) (← links)
• Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus (Q35621741) (← links)
• Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? (Q35636514) (← links)
• A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies (Q35742512) (← links)
• Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection (Q35752812) (← links)
• Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. (Q35870930) (← links)
• Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model. (Q35874788) (← links)
• Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. (Q35878689) (← links)
• A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides (Q35879410) (← links)
• Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. (Q35905947) (← links)
• Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. (Q35964704) (← links)
• Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures (Q36086642) (← links)
• Virus dynamics and drug therapy (Q36244920) (← links)
• Converting cancer therapies into cures: lessons from infectious diseases (Q36301709) (← links)
• Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants (Q36313247) (← links)
• Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection (Q36322100) (← links)
• Biochemical mechanism of HIV-1 resistance to rilpivirine (Q36368294) (← links)
• Antiretroviral therapy 2006: pharmacology, applications, and special situations (Q36533088) (← links)
• Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group (Q36536351) (← links)
• Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma (Q36542026) (← links)
• Comparison of the Amplicor HIV-1 monitor test and the nucleic acid sequence-based amplification assay for quantitation of human immunodeficiency virus RNA in plasma, serum, and plasma subjected to freeze-thaw cycles (Q36548250) (← links)
• Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors (Q36689086) (← links)
• Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase by a stavudine analogue, 4'-ethynyl stavudine triphosphate (Q36703003) (← links)
• Comparison of G-to-A mutation frequencies induced by APOBEC3 proteins in H9 cells and peripheral blood mononuclear cells in the context of impaired processivities of drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants (Q36747913) (← links)
• Antiretroviral treatment of HIV infection: Swedish recommendations 2007. (Q36852859) (← links)
• Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques (Q36954674) (← links)
• Clinical significance of human immunodeficiency virus type 1 replication fitness (Q36969857) (← links)
• The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. (Q37018369) (← links)
• HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. (Q37090735) (← links)
• Reverse transcriptase inhibitors as potential colorectal microbicides (Q37190754) (← links)
• How effectively can HIV phylogenies be used to measure heritability? (Q37363152) (← links)
• Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile (Q37409900) (← links)
• Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay (Q37497318) (← links)
• Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine (Q37590309) (← links)
• Viral dynamics in hepatitis B virus infection (Q37638400) (← links)
• Lamivudine for the treatment of HIV. (Q37650410) (← links)
• HIV testing and antiretroviral treatment strategies for prevention of HIV infection: impact on antiretroviral drug resistance. (Q37935116) (← links)